{"schema_version":"secwatch.filing_event.v1","accession":"0000096943-23-000088","form_type":"8-K","ticker":"TFX","cik":"0000096943","company_name":"TELEFLEX INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.121312+00:00","generated_at":"2026-06-12T10:52:50.220269+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teleflex Q2 revenue up 5.9% constant currency; revenue guidance raised, adjusted EPS maintained","bullets":["Q2 revenues $743.3M, +5.9% constant currency YoY; GAAP diluted EPS $2.35, adjusted diluted EPS $3.41.","FY2023 GAAP revenue growth guidance raised to 5.80%-6.55%; constant currency raised to 5.50%-6.25%.","FY2023 GAAP diluted EPS guidance lowered to $7.33-$7.93; adjusted diluted EPS maintained at $13.00-$13.60.","Announced acquisition of Palette Life Sciences AB for rectal spacer to expand Interventional Urology franchise.","Interventional Urology constant currency revenue declined 2.3% YoY; OEM segment grew 19.8% constant currency."],"urls":{"canonical":"https://secwatch.observer/filing/0000096943-23-000088","json":"https://secwatch.observer/filing/0000096943-23-000088.json","markdown":"https://secwatch.observer/filing/0000096943-23-000088.md","text":"https://secwatch.observer/filing/0000096943-23-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/96943/000009694323000088/0000096943-23-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/96943/000009694323000088/tfx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:52:50.220269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9edc5ed0944b56abd388f2bf79dca63bc0a424f8","claim":"TELEFLEX INC reported the second quarter ended July 2, 2023 results: revenue $743.3 million, EPS $2.35. Guidance raised.","evidence_excerpt":"Teleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended July 2, 2023 . Second quarter financial summary • Revenues of $743.3 million, up 5.5% compared to the prior year period; up 5.9% on a constant currency basis • GAAP diluted EPS from continuing operations of $2.35, compared to $2.23 in the prior year period • Adjusted diluted EPS from continuing operations of $3.41, compared to $3.39 in the prior year period 2023 guidance summary • Raising GAAP revenue growth guidance to 5.80% to 6.55% • Raising the low end of constant currency revenue growth guidance to 5.50% to 6.25% • Lowering GAAP EPS from continuing operations guidance to $7.33 to $7.93 • Maintaining adjusted diluted EPS from continuing operations guidance of $13.00 to $13.60, reflecting estimated dilution from the acquisition of Palette Life Sciences AB","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/96943/000009694323000088/0000096943-23-000088-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended July 2, 2023"},{"label":"Revenue","value":"$743.3 million"},{"label":"EPS","value":"$2.35"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}